Mizuho raised the firm’s price target on Establishment Labs to $110 from $95 and keeps a Buy rating on the shares. The company presented three-year data for its U.S. Motiva IDE study that showed persistent safety of Motiva, with no capsular contracture or rupture rate adverse event increases since two-year data, the analyst tells investors in a research note. The firm’s bull case sees potential U.S. approval and launch in early 2024.
Protect Your Portfolio Against Market Uncertainty
- Discover companies with rock-solid fundamentals in TipRanks' Smart Value Newsletter.
- Receive undervalued stocks, resilient to market uncertainty, delivered straight to your inbox.
Published first on TheFly
See today’s best-performing stocks on TipRanks >>
Read More on ESTA:
- Establishment Labs says update on Motiva U.S. IDE study presented
- Establishment Labs price target raised to $105 from $100 at BTIG
- Establishment Labs announces launch of Mia Femtech in Japan
- Establishment Labs has surpassed three million Motiva devices in market
- Sell these stocks now, proven algorithm says